{"author_url":"https://blog.hatena.ne.jp/okumi/","blog_url":"https://okumi.hatenablog.com/","provider_name":"Hatena Blog","published":"2022-06-02 18:37:19","author_name":"okumi","categories":[],"blog_title":"\u30ea\u30d7\u30ed\u306a\u65e5\u8a18","title":"Analysis of Medication Abortion Risk and the FDA report \u201cMifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018\u201d","provider_url":"https://hatena.blog","type":"rich","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fokumi.hatenablog.com%2Fentry%2F2022%2F06%2F02%2F183719\" title=\"Analysis of Medication Abortion Risk and the FDA report \u201cMifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018\u201d - \u30ea\u30d7\u30ed\u306a\u65e5\u8a18\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","version":"1.0","width":"100%","description":"\u5fd8\u5099\u9332 Analysis of Medication Abortion Risk and the FDA report \u201cMifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2018\u201d\u6982\u8981\u3092\u8a66\u8a33\u3057\u3066\u304a\u304d\u307e\u3059\u3002 \u6982\u8981 FDA\u306e\u5831\u544a\u66f8\u300cMifepristone U.S. PostMarketing Adverse Events Summary through 12/31/2018 \u300d\u306b\u306f\u3001\u672c\u5264\u306e\u4f7f\u7528\u306b\u95a2\u9023\u3059\u308b\u6709\u5bb3\u4e8b\u8c61\u304c\u8a18\u8f09\u3055\u308c\u3066\u3044\u307e\u3059\u3002 \u30df\u30d5\u30a7\u30d7\u30ea\u30b9\u30c8\u30f3\u3068\u4e2d\u7d76\u3068\u306e\u56e0\u679c\u95a2\u4fc2\u306e\u53ef\u80fd\u6027\u306b\u304b\u304b\u308f\u3089\u305a\u3001\u30df\u30d5\u30a7\u30d7\u30ea\u30b9\u30c8\u30f3\u306e\u2026","url":"https://okumi.hatenablog.com/entry/2022/06/02/183719","height":"190","image_url":null}